Bienhoff Stephen E, Smith Eric S, Roycroft Linda M, Roberts Elizabeth S, Baker Larry D
Department of New Product Development, Novartis Animal Health US, Inc., Greensboro, NC 27408, USA.
ISRN Vet Sci. 2012 Jan 23;2011:593015. doi: 10.5402/2011/593015. Print 2011.
The efficacy and safety of deracoxib administered at 1-2 mg/kg/day for 3 days was assessed for the control of postoperative pain and inflammation associated with dental surgery in dogs. Client-owned dogs scheduled for dental extractions were premedicated with butorphanol and randomly assigned to receive either deracoxib (n = 31) or placebo (n = 31) preoperatively and again once daily for 2 additional days. Dogs were evaluated prior to and after surgery using a modified Glasgow Composite Pain Scale (mGCPS). Dogs could be rescued at any time if they scored ≥4 on the mGCPS or in cases of obvious discomfort. Rescued dogs were considered treatment failures for determining treatment response and were removed from the study. Of the 62 dogs enrolled, 57 were usable for the efficacy analyses and all were assessed for safety. Four of 27 deracoxib-treated dogs (14.8%) were rescued compared to 20 of 30 placebo dogs (66.7%) (P = 0.0006). Deracoxib-treated dogs also had numerically lower mGCPS scores. Eight of 31 deracoxib dogs (26%) had adverse events reported compared to 6 of 31 placebo dogs (19%). Results indicate perioperative administration of deracoxib to dogs at 1-2 mg/kg/day for 3 days significantly improves analgesia after dental surgery.
评估了以1-2毫克/千克/天的剂量给予德拉考昔3天，对控制犬牙科手术后疼痛和炎症的疗效及安全性。计划进行拔牙的客户拥有的犬，术前用布托啡诺进行预处理，并随机分配在术前接受德拉考昔（n = 31）或安慰剂（n = 31），并在接下来的2天每天再次给药一次。使用改良的格拉斯哥综合疼痛量表（mGCPS）在手术前后对犬进行评估。如果犬在mGCPS上的得分≥4或出现明显不适，可随时进行解救。在确定治疗反应时，解救的犬被视为治疗失败，并从研究中剔除。在纳入的62只犬中，57只可用于疗效分析，所有犬均进行了安全性评估。27只接受德拉考昔治疗的犬中有4只（14.8%）被解救，而30只接受安慰剂治疗的犬中有20只（66.7%）被解救（P = 0.0006）。接受德拉考昔治疗的犬mGCPS得分在数值上也较低。31只接受德拉考昔治疗的犬中有8只（26%）报告有不良事件，而31只接受安慰剂治疗的犬中有6只（19%）报告有不良事件。结果表明，以1-2毫克/千克/天的剂量对犬围手术期给予德拉考昔3天，可显著改善牙科手术后的镇痛效果。
